
pmid: 28843367
Isolated reoperative tricuspid valve replacement is one of the highest risk operations classified in the Society of Thoracic Surgeons registry, particularly in the setting of preexisting right ventricular dysfunction. Transcatheter tricuspid valve-in-valve implantation represents an attractive alternative to redo surgery in patients with tricuspid bioprosthetic valve degeneration who are considered high-risk or unsuitable surgical candidates. In this review article, the authors discuss the emergence of transcatheter tricuspid valve-in-valve therapy, preprocedural echocardiographic assessment of tricuspid bioprosthetic valve dysfunction, periprocedural imaging required for tricuspid valve-in-valve implantation, and postprocedural assessment of tricuspid transcatheter device function.
Bioprosthesis, Heart Valve Prosthesis Implantation, Reoperation, Cardiac Catheterization, Heart Valve Diseases, Prosthesis Design, Prosthesis Failure, Echocardiography, Heart Valve Prosthesis, Humans, Tricuspid Valve
Bioprosthesis, Heart Valve Prosthesis Implantation, Reoperation, Cardiac Catheterization, Heart Valve Diseases, Prosthesis Design, Prosthesis Failure, Echocardiography, Heart Valve Prosthesis, Humans, Tricuspid Valve
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 15 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
